Regeneron and Sanofi's Dupixent Secures FDA Approval for COPD Treatment

Regeneron Pharmaceuticals and Sanofi saw their shares rise on Friday following the FDA’s approval of their drug Dupixent for chronic obstructive pulmonary disease (COPD). This marks Dupixent as the first biologic medicine approved in the U.S. specifically for COPD, a condition that impairs airflow and harms lung function.

Clinical trials demonstrated that Dupixent reduced the annualized rate of moderate or severe COPD by at least 30% in two Phase 3 studies. Previously, the drug received approvals for treating atopic dermatitis and asthma.

On the stock market, Regeneron’s shares increased by 0.2%, while Sanofi’s U.S. shares rose by 1.1%. Both companies have seen their stock prices climb approximately 19% and 16%, respectively, since the beginning of the year.